COMMUNIQUÉS West-GlobeNewswire

PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
25/02/2026
SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
25/02/2026
ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments [...]
OraSure Announces Fourth Quarter 2025 Financial Results
25/02/2026
BETHLEHEM, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
25/02/2026
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]
NANOBIOTIX to Participate in Investor Conferences in March
25/02/2026
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “ Company ”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
Q4 2025 net product revenue for ZORYVE ® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025 Full year 2025 net product revenue for ZORYVE was $372.1 million, an [...]
Park Dental Partners Announces Fourth Quarter and Full-Year Results
25/02/2026
MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its fourth-quarter [...]
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
25/02/2026
On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026 Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three [...]
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
25/02/2026
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be [...]
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
25/02/2026
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported [...]
Premier Health Reports 2026 First Quarter Results
25/02/2026
MONTRÉAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSX-V: PHA ) (the “ Company ”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial [...]
Surrozen to Present at Upcoming Healthcare Investor Conference
25/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling [...]
Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results
25/02/2026
Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company [...]
Information on the total number of voting rights and shares
25/02/2026
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Pennant Reports Fourth Quarter and Fiscal Year 2025 Results
25/02/2026
Conference Call and Webcast scheduled for tomorrow, February 26, 2026 at 10:00 am MT EAGLE, Idaho, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
25/02/2026
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income ( 1) of $161 Million, [...]
LENSAR® Provides Update on Pending Acquisition by Alcon
25/02/2026
ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
25/02/2026
Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027 Phase 3 [...]
Chemed Reports Fourth-Quarter 2025 Results
25/02/2026
CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation [...]

Pages